Targeted care for chronic plantar heel pain: Shockwave therapy for bone marrow lesions (the BALSA trial)
Efficacy of shockwave therapy for pain in participants with a bone marrow lesion phenotype of chronic plantar heel pain: the BALSA trial.
Menzies Institute for Medical Research, University of Tasmania
90 participants
Sep 2, 2024
Interventional
Conditions
Summary
Up to 50% of people with chronic plantar heel pain have a bone marrow lesion (BML) in the calcaneus. Calcaneal bone marrow lesions are high signal lesions on MRI that are associated with having chronic plantar heel pain and with poorer longer-term pain and function outcomes. Shockwave therapy is an approved therapeutic device in Australia for treating musculoskeletal pain, including plantar heel pain. It emits high levels of acoustic energy that has been shown to improve pain and shrink bone marrow lesions at other body sites, but it has never been tested for its effect on pain in people with a bone marrow lesion sub-type of chronic plantar heel pain. The primary aim of this study therefore is to determine whether shockwave therapy is effective at improving pain in a BML-positive subgroup of participants with chronic plantar heel pain. Ninety participants will be randomly allocated to either an active or sham shockwave group (45 per arm), each receiving one treatment per week over three weeks. Pain will be assessed by validated questionnaire at baseline, 4- and 12-months to determine if shockwave is effective at reducing pain. Secondary measures for physical function and quality of life will be assessed at baseline, 4- and 12-months and perception of global rating of change assessed at 4- and 12-months. As an exploratory analysis BML size will be measured by MRI at baseline and 4-months to determine if change in BML is associated with change in pain.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Shockwave & advice Three sessions of radial shockwave, directed at the plantar calcaneus, will be provided at weekly intervals, delivered using the same branded machine (EMS Swiss DolorClast Master Touch). Visualising the bone marrow lesion (BML) location on MRI is not required as all lesions must be in a plantar location and therefore accessible to topical shockwave application. However shockwave application will be directed to the most painful aspect of the plantar heel, marked prior to application with an indelible pen. Each session will last less than 20 minutes and details of treatment (machine settings, total session energy dose, maximum energy intensity, participant response) will be recorded on a treatment log for each participant. Treatment parameters will be as per industry (EMS) and societal recommended guidelines (International Society for Medical Shockwave Treatment, ISMST) with intensity ranging from 2-4 bar pressure for a minimum of 2000 pulses using a 15mm diameter applicator head, at a frequency ranging from 4-10Hz based on comfort. As is standard clinical practice, the intent is to deliver the highest tolerable energy based on a progressive increase in bar pressure, a term referred to by ISMST as ‘pain-adapted dosing’. As well as aiming for maximum bar pressure, we will seek to deliver a minimum total energy treatment dose across all 3 sessions. For this study for the purpose of quantifying a per protocol energy dose, we will target a minimum total energy dose of 500 mJ/mm^2. The Master Touch unit can convert bar pressure into energy flux density (mJ/mm^2), which when multiplied by the number of pulses delivered, computes the total sessional energy dose. To reach 500 mJ/mm^2 across 3 sessions, an average bar pressure above 2.2 is required. This places this dose in a clinically therapeutic range. If it is evident that the cumulative dose is going to be short of the targeted 500 mJ/mm^2, the clinician may increase the number of pulses in subsequent sessions (e.g. to 2500), however the priority is always to deliver the maximum peak energy dose. If participants do not receive the minimum dose across the 3 sessions, a 4th ‘top-up’ session will be offered. If a top-up session is required, this will be matched with a top-up session to an equal number of participants in the sham group. Sessions will be booked in consecutive weeks in advance however we will allow missed sessions to be caught up with treatment gaps not exceeding 2 weeks. An advice sheet detailing flare management, footwear and activity recommendations will be provided to both groups.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12624000260527